Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

Alimentary Pharmacology and Therapeutics - Tập 47 Số 4 - Trang 485-493 - 2018
S. Tadbiri1, Laurent Peyrin–Biroulet2, Mélanie Serrero3, Philippe Marteau4, Benjamin Pariente5, Xavier Roblin6, Anthony Buisson7, Lila Bouadma8, Caroline Trang-Poisson9, Romain Altwegg10, T. Vaysse11, Julien Kirchgesner12, Stéphane Nancey13, David Laharie14, Matthieu Allez15, Guillaume Savoye16, Cyrielle Gilletta17, Charlotte Gagnière1, Lucine Vuitton18, S Viennot19, Alexandre Aubourg20, Anne-Laure Pelletier21, Guillaume Bouguen22, Véred Abitbol23, Mathurin Fuméry24, Pierre Desreumaux25, Yoram Bouhnik8, Aurélien Amiot1
1Creteil, France
2Nancy – France
3Marseille – France
4Nice, France
5Lille – France
6Saint‐Etienne France
7Clermont‐Ferrand France
8Clichy – France
9Nantes – France
10Montpellier – France
11Kremlin Bicêtre France
12CHU Saint-Antoine [AP-HP] (184, rue du Faubourg Saint-Antoine 75571 Paris cedex 12 - France)
13Lyon – France
14Bordeaux – France
15Saint Louis Hospital, Paris, France
16ADEN - Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (22 bd Gambetta 76183 Rouen Cedex - France)
17Toulouse, France.
18Besançon – France
19Caen – France
20Tours – France
21Bichat Hospital, Paris, France
22Service des Maladies de l'Appareil Digestif [CHU Rennes] (2 Rue Henri le Guilloux 35000 Rennes - France)
23Cochin Hospital, Paris, France
24Amiens – France
25Service de rhumatologie [CHU Henri Mondor] (France)

Tóm tắt

SummaryBackgroundThe effectiveness of vedolizumab as a treatment for extraintestinal manifestations (EIM) is questionable due to its gut‐specificity.AimTo assess effectiveness of vedolizumab for EIM in patients with inflammatory bowel disease (IBD) in a large real‐life experience cohort.MethodsBetween June and December 2014, 173 patients with Crohn's disease and 121 with ulcerative colitis were treated with vedolizumab. Patients were followed until week 54. EIM activity was assessed at weeks 0, 6, 14, 22, 30 and 54 by using a 3‐step scale: complete remission, partial response and no response.ResultsAt baseline, 49 (16.7%) patients had EIMs of which 47 had inflammatory arthralgia/arthritis, four had cutaneous lesions and two had both rheumatologic and skin EIM. At week 54, 21 (44.7%) patients had complete remission for inflammatory arthralgia/arthritis and three (75%) for cutaneous EIM. In multivariate analysis, complete remission of inflammatory arthralgia/arthritis was associated with clinical remission of IBD (OR = 1.89, IC95% [1.05‐3.41], P = .03) and recent onset of inflammatory arthralgia/arthritis (OR = 1.99, IC95% [1.12‐3.52], P = .02). During the follow‐up period, 34 (13.8%) patients without any EIM at baseline, developed incident cases of inflammatory arthralgia/arthritis consisting mostly of peripheral arthralgia without evidence of arthritis and 14 (4.8%) incident cases of paradoxical skin manifestation.ConclusionVedolizumab therapy is commonly associated with improvement in EIM. This was associated with quiescent IBD and recent EIM. However, paradoxical skin manifestation and inflammatory arthralgia/arthritis may occur upon vedolizumab therapy.

Từ khóa


Tài liệu tham khảo

10.1038/ajg.2009.579

10.1093/ecco-jcc/jjv213

10.1111/apt.12680

10.1111/apt.13217

10.1586/eci.10.40

10.1056/NEJMoa1215734

10.1056/NEJMoa1215739

10.1053/j.gastro.2014.05.008

10.1038/ajg.2016.236

10.1111/apt.13594

10.1111/apt.13813

10.1097/MIB.0000000000000561

10.1016/j.cgh.2016.02.016

10.1136/annrheumdis-2016-210233

10.1002/ibd.3780040210

Salmi M, 1950, Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules, J Immunol Baltim Md, 2001, 4650

10.1136/annrheumdis-2014-206323

10.1136/ard.2003.006965

10.1111/apt.14167

10.1056/NEJMoa050516

10.1016/S0140-6736(80)92767-1

10.1097/MIB.0000000000000548

10.1002/art.1780270401

10.1016/j.jbspin.2009.12.005

10.1136/annrheumdis-2012-201884

10.1111/apt.13352

10.1093/ecco-jcc/jjv159

10.1097/MEG.0000000000000643

10.1016/j.cgh.2008.05.010

10.1097/MIB.0000000000001109

10.1038/ajg.2015.233

10.1053/jhep.2001.24231

10.1016/j.cgh.2016.06.025

Louis E, 2016, Adalimumab treatment reduces extraintestinal manifestations in patients with moderate to severe crohn's disease: a pooled analysis, J Crohns Colitis, 10, S351

Briskin M, 1997, Human mucosal addressin cell adhesion molecule‐1 is preferentially expressed in intestinal tract and associated lymphoid tissue, Am J Pathol, 151, 97

Wendling D, 2017, Arthritis occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report, Joint Bone Spine Rev Rhum

10.1136/annrheumdis-2016-211011

10.1038/nrgastro.2012.125

10.1016/j.autrev.2013.06.005

10.1016/j.cgh.2010.07.022

10.1111/j.1365-2036.2011.04866.x

10.1016/S0016-5085(03)00701-7

10.1684/ejd.2011.1164

Suh HY, 2017, Exacerbation of infliximab‐induced paradoxical psoriasis after ustekinumab therapy, J Dermatol

10.1111/bjd.13645

10.1093/rheumatology/kev263

10.1136/gutjnl-2012-302853

10.1038/ajg.2015.205

10.1136/gut.2003.018515

10.1111/j.1572-0241.2000.03363.x

Duffin KC, 2017, Evaluation of the physician global assessment and body surface area composite tool for assessing psoriasis response to apremilast therapy: results from ESTEEM 1 and ESTEEM 2, J Drugs Dermatol, 16, 147

10.1111/apt.12929

Thông tin
Thông tin xuất bản

Alimentary Pharmacology and Therapeutics

Tập 47 Số 4

485-493

Thông tin tác giả